San Diego-based ADARx Pharmaceuticals, a biotechnology company which is developing RNA targeting therapeutics, said Wednesday that it has raised $75M in a Series B funding. The funding was co-led by SR One Capital Management and OrbiMed Advisors, and also included Sirona Capital and Lilly Asia Ventures. According to the company, the funding will go to advance and expand its pipeline of RNA targeting therapeutics. AdaRx is led by President and CEO Zhen Li, Ph.D. The company said it is developing a proprietary RNA targeting platform, including oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies. The company said its platform is aimed at treating diseases across a range of therapeutic areas including genetic, cardiometabolic, and central nervous system diseases.